Send to

Choose Destination
Clin Case Rep. 2016 Oct 17;4(12):1120-1121. eCollection 2016 Dec.

A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.

Author information

Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA.
Yale Comprehensive Cancer Center and VA Connecticut Healthcare System West Haven Connecticut USA.
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA.


Ibrutinib is a first-in-class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.


Arrhythmia; cardiomyopathy; ibrutinib; mantle cell lymphoma; tyrosine kinase inhibitor

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center